预约演示
更新于：2025-02-24
Gadopentetate Dimeglumine
钆喷酸葡胺
更新于：2025-02-24
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1988-06-02), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H36GdN4O15 |
InChIKeyLZQIEMULHFPUQY-BMWGJIJESA-J |
CAS号86050-77-3 |
关联
34
项与 钆喷酸葡胺 相关的临床试验NCT04776187
Safety Evaluation of Linear and Macrocyclic Gadolinium-Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging (Interventional Prospective Study) Clinical Trial Protocol
NCT02371798
Diagnosing Endolymphatic Hydrops in Patients With Meniere Disease Using Magnetic Resonance Imaging With Intravenous Gadolinium Administration
NCT02278510
A Pilot Trial of Intraparenchymally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Requiring Stereotactic Biopsy
100 项与 钆喷酸葡胺 相关的临床结果
登录后查看更多信息
100 项与 钆喷酸葡胺 相关的转化医学
登录后查看更多信息
100 项与 钆喷酸葡胺 相关的专利（医药）
登录后查看更多信息
5,716
项与 钆喷酸葡胺 相关的文献（医药）2025-02-01CLINICAL RADIOLOGY
Comparative study of 3D-T2WI vs. 3D-T2-FLAIR MRI in displaying human meningeal lymphatics vessels
Article
作者: Fang, Y ; Lai, Tianmin ; Zhao, Y ; Lin, Y ; Zhao, Yihan ; Fu, Ying ; Song, X ; Lai, T. ; Sun, Y. ; Fang, Yaofeng ; Sun, Yuyu ; Bao, Q. ; Hu, Tao ; Zhao, Y. ; Bao, Quan ; Song, Xin ; Hu, T ; Fang, Y. ; Lin, Y. ; Song, X. ; Sun, Y ; Hu, T. ; Bao, Q ; Lin, Yi ; Lai, T
AIM:
Various magnetic resonance imaging (MRI) sequences can be utilized to visualize human meningeal lymphatic vessels (MLVs) for investigating the associations between MLVs and central nervous system (CNS) disorders. This study aimed to compare the quality of contrast-enhanced 3D-T2WI and 3D-T2-fluid-attenuated inversion recovery (FLAIR) MRI sequences to display human MLVs.
MATERIALS AND METHODS:
Sixty-two patients (27 males, 35 females; mean age 55.8 ± 14.9 years) underwent 3D-T2WI and 3D-T2-FLAIR scan in combination with Gd-DTPA injection to show MLVs.
RESULTS:
(1) The positivity rates of the 3D-T2WI sequence were 98.4%, 29.0%, and 46.8%, around the dural sinus, middle meningeal artery, and ethmoid sinus, respectively. The positivity rates of the 3D-T2-FLAIR sequence were 100%, 48.4%, and 66.1%, respectively. The positivity rate was significantly higher with the 3D-T2-FLAIR sequence compared with the 3D-T2WI sequence for the middle meningeal artery and ethmoid sinus regions (p < 0.05). (2) In patients with brain lesions and intracranial space-occupying lesions, the positivity rate was significantly higher with the 3D-T2-FLAIR sequence compared with the 3D-T2WI sequence for the middle meningeal artery and ethmoid sinus regions (p < 0.05). (3) The mean cross-sectional areas of MLVs around the dural sinus, middle meningeal artery, and ethmoid sinus were all higher using the 3D-T2-FLAIR sequence compared with the 3D-T2WI sequence at all three sites (p < 0.01). (4) The signal intensity was significantly higher using the 3D-T2-FLAIR sequence compared with the 3D-T2WI sequence around the dural sinus and ethmoid sinus (p < 0.001).
CONCLUSION:
The 3D-T2-FLAIR sequence contrast-enhanced scan showed superior visualization of MLVs compared with the 3D-T2WI sequence.
2025-01-29ACS Applied Materials & Interfaces
Electrochemical Filtration of Gadolinium from Patient Urine after Magnetic Resonance Imaging
Article
作者: Wijesinghe, Sethma ; Allen, Matthew J. ; Kovaci, Christa ; Wang, Bingwen ; Luo, Long ; Ranaweera, Ruchiranga ; Weerarathna, Udeshika
The widespread use of gadolinium-based contrast agents for magnetic resonance imaging (MRI) in recent decades has led to a growing demand for Gd and raised environmental concerns due to their direct discharge into wastewater systems. In response, we developed an electrochemical filtration method to recover Gd from patient urine following contrast-enhanced MRI. This method involves modifying a conventional vacuum filtration apparatus by introducing electrodes into the filter membrane, creating a strong electric field of ∼5 kV/m and a steep three-zone pH gradient within the filter membrane. These electric and pH fields facilitate the dissociation of Gd-based contrast agents, releasing GdIII ions, electrophoretic separation of GdIII and its ligand, and eventually precipitation and trapping of GdIII as GdPO4 and Gd(OH)3 on the filter membrane. Using gadopentetate dimeglumine (GdDTPA) as a model Gd-based contrast agent, we achieved a Gd trapping efficiency of ∼70% for artificial and real urine samples. For macrocyclic Gd-based contrast agents such as gadoterate meglumine (GdDOTA), the Gd trapping efficiency decreased to 25.4% due to the slow dissociation kinetics of macrocyclic contrast agents. However, the trapping efficiency can be improved to ∼40% by allowing the macrocyclic contrast agent to predissociate in an acidic environment before electrochemical filtration. The Gd trapped on the filter membrane can be recovered by thermal treatment in a muffle furnace. After thermal treatment, the reclaimed Gd from the real urine sample was primarily identified as GdPO4. This electrochemical filtration design offers a straightforward and practical approach to recovering Gd from contrast-enhanced MRI scans, addressing the increasing demand for Gd and helping alleviate concerns about Gd contamination in surface water.
2025-01-28ACS Nano
PEGylated Ultrasmall Iron Oxide Nanoparticles as MRI Contrast Agents for Vascular Imaging and Real-Time Monitoring
Article
作者: Xu, Keyang ; Cao, Xiaoyi ; Gao, Mingyuan ; Lu, Kuan ; Zeng, Jianfeng ; Zhang, Ruru ; Wang, Hongzhao ; Wang, Ning ; Li, Cang ; Cai, Wu ; Yang, Zhe
Accurate imaging evaluations of pre- and post-treatment of cardiovascular diseases are pivotal for effective clinical interventions and improved patient outcomes. However, current imaging methods lack real-time monitoring capabilities with a high contrast and resolution during treatments. This study introduces PEGylated ultrasmall iron oxide nanoparticles (PUSIONPs), which have undergone comprehensive safety evaluations, boasting an r1 value of 6.31 mM-1 s-1, for contrast-enhanced magnetic resonance angiography (MRA). Systematic comparisons against common clinical methods in rabbits reveal that PUSIONPs-enhanced MRA exhibited improved vascular contrast, clearer vascular boundaries, and superior vessel resolution. Moreover, owing to their nanosize, PUSIONPs demonstrate significantly prolonged blood circulation compared to small molecular contrast agents such as Magnevist and Ultravist. This extended circulation enables captivating real-time monitoring of thrombolysis treatment for up to 4 h in rabbit models postsingle contrast agent injection. Additionally, in larger animal models such as beagles and Bama minipigs, PUSIONPs-enhanced MRA also showcases superior contrast effects, boundary delineation, and microvessel visualization, underscoring their potential to transform cardiovascular imaging, particularly in real-time monitoring and high-resolution visualization during treatment processes.
100 项与 钆喷酸葡胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 造影剂 | 美国 | 1988-06-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心血管畸形 | 临床3期 | - | 2003-12-01 | |
| 病理性缩窄 | 临床3期 | - | 2003-12-01 | |
| 肾动脉阻塞 | 临床3期 | - | 2003-12-01 | |
| 外周血管疾病 | 临床3期 | - | 2003-03-01 | |
| 脑转移瘤 | 临床3期 | 日本 | 2003-02-01 | |
| 心肌梗塞 | 临床2期 | 美国 | 2006-03-01 | |
| 心肌梗塞 | 临床2期 | 阿根廷 | 2006-03-01 | |
| 外周动脉疾病 | 临床2期 | 日本 | 2004-07-01 | |
| 血管动脉疾病 | 临床2期 | 日本 | 2004-07-01 | |
| 原发性免疫缺陷疾病 | 临床2期 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 2 | 3 Tesla Magnetic Resonance Imaging+Magnevist® (Intravenous (IV) administration of MRI contrast agent) | 夢壓餘簾願壓夢窪壓廠(夢醖膚積鏇膚醖繭醖窪) = 鏇鹽顧簾鏇窪糧衊壓窪 糧鏇製築觸顧鬱築壓淵 (築範網餘衊鬱餘鑰鑰衊, 簾積膚鑰顧膚醖築築淵 ~ 觸醖選壓簾艱淵積廠衊) 更多 | - | 2018-07-11 | ||
N/A | 17 | 構網衊夢醖遞壓鬱壓網(網衊壓遞窪夢獵蓋膚憲) = 遞鏇製餘鑰網糧選繭築 膚選淵繭簾製醖艱簾夢 (襯鹽願窪築範願壓廠憲, 鏇構鏇觸廠廠網鬱蓋壓 ~ 繭廠觸鬱簾鹽範壓獵鑰) 更多 | - | 2017-06-14 | |||
N/A | 6 | 鏇窪憲構艱艱窪遞淵網(窪構積窪衊醖繭鏇艱憲) = 網獵積簾衊襯範餘製齋 範網窪積淵壓淵鹹鬱積 (獵醖遞廠選製憲鑰遞壓, 網簾蓋膚糧顧淵糧簾夢 ~ 鏇繭製觸範繭簾艱鑰鏇) 更多 | - | 2016-02-12 | |||
N/A | - | IV contrast media (Gadopentetate Dimeglumine) | 鏇餘壓鹽襯膚鑰範蓋廠(鏇積鏇糧艱鏇膚獵壓艱) = This is a rare case of grand mal seizures that occurred in a patient without any previous seizure history and not immediately after the injection of the contrast media, as it was till now reported in the literature. 鏇淵廠構繭獵衊餘壓鏇 (繭艱衊構鹹鹽鹹壓獵憲 ) | - | 2013-06-26 | ||
临床3期 | - | 46 | 積構膚製築窪選築蓋衊(廠廠艱廠鑰糧積廠鹽顧) = 淵範簾糧鹹築鹹繭網製 製簾顧夢壓餘醖壓糧遞 (鹹鬱壓淵醖淵鹹衊廠觸 ) 更多 | 积极 | 2013-04-01 | ||
積構膚製築窪選築蓋衊(廠廠艱廠鑰糧積廠鹽顧) = 夢餘鑰鹹遞憲構簾範觸 製簾顧夢壓餘醖壓糧遞 (鹹鬱壓淵醖淵鹹衊廠觸 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用